NO20014851D0 - Renal cellekarsinombehandling - Google Patents

Renal cellekarsinombehandling

Info

Publication number
NO20014851D0
NO20014851D0 NO20014851A NO20014851A NO20014851D0 NO 20014851 D0 NO20014851 D0 NO 20014851D0 NO 20014851 A NO20014851 A NO 20014851A NO 20014851 A NO20014851 A NO 20014851A NO 20014851 D0 NO20014851 D0 NO 20014851D0
Authority
NO
Norway
Prior art keywords
cell carcinoma
renal cell
carcinoma treatment
treatment
renal
Prior art date
Application number
NO20014851A
Other languages
English (en)
Other versions
NO20014851L (no
NO328983B1 (no
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20014851D0 publication Critical patent/NO20014851D0/no
Publication of NO20014851L publication Critical patent/NO20014851L/no
Publication of NO328983B1 publication Critical patent/NO328983B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20014851A 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. NO328983B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
PCT/US2000/009127 WO2000061174A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha for renal cell carcinoma treatment

Publications (3)

Publication Number Publication Date
NO20014851D0 true NO20014851D0 (no) 2001-10-05
NO20014851L NO20014851L (no) 2001-12-07
NO328983B1 NO328983B1 (no) 2010-07-05

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014851A NO328983B1 (no) 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom.

Country Status (24)

Country Link
EP (2) EP1535623B1 (no)
JP (2) JP4721488B2 (no)
CN (1) CN1367702A (no)
AR (1) AR029160A1 (no)
AT (2) ATE419002T1 (no)
AU (2) AU777406B2 (no)
BR (1) BR0009644A (no)
CA (1) CA2303752A1 (no)
CO (1) CO5170412A1 (no)
CY (1) CY1108919T1 (no)
DE (2) DE60041291D1 (no)
DK (2) DK1535623T3 (no)
ES (2) ES2319777T3 (no)
HK (2) HK1032533A1 (no)
HU (1) HU230271B1 (no)
MX (1) MXPA00003401A (no)
MY (1) MY155221A (no)
NO (1) NO328983B1 (no)
NZ (1) NZ514629A (no)
PE (1) PE20010026A1 (no)
PT (2) PT1535623E (no)
TW (2) TWI310314B (no)
WO (1) WO2000061174A2 (no)
ZA (1) ZA200108169B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1535623E (pt) * 1999-04-08 2009-03-19 Schering Corp Tratamento para carcinoma de células renais
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
CN102985088B (zh) 2010-04-01 2017-02-08 奥科瑞纳有限公司 肾细胞癌的改进治疗
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
IL138221A0 (en) * 1998-03-26 2001-10-31 Schering Corp Formulations for protection of peg-interferon alpha conjugates
PT1535623E (pt) * 1999-04-08 2009-03-19 Schering Corp Tratamento para carcinoma de células renais

Also Published As

Publication number Publication date
MY155221A (en) 2015-09-30
CO5170412A1 (es) 2002-06-27
ES2319777T3 (es) 2009-05-12
DE60041291D1 (de) 2009-02-12
JP3712914B2 (ja) 2005-11-02
DK1535623T3 (da) 2009-04-27
EP1043025A3 (en) 2000-12-20
ZA200108169B (en) 2003-01-06
PT1043025E (pt) 2005-09-30
CY1108919T1 (el) 2014-07-02
HK1032533A1 (en) 2001-07-27
ATE296638T1 (de) 2005-06-15
ATE419002T1 (de) 2009-01-15
HUP0200781A3 (en) 2002-09-30
AR029160A1 (es) 2003-06-18
HU230271B1 (hu) 2015-11-30
EP1535623B1 (en) 2008-12-31
JP2001288110A (ja) 2001-10-16
AU4204400A (en) 2000-11-14
JP4721488B2 (ja) 2011-07-13
AU777406B2 (en) 2004-10-14
JP2000319196A (ja) 2000-11-21
TW200526243A (en) 2005-08-16
DK1043025T3 (da) 2005-07-04
TWI310314B (en) 2009-06-01
WO2000061174A2 (en) 2000-10-19
NZ514629A (en) 2004-02-27
DE60020442D1 (de) 2005-07-07
EP1043025A2 (en) 2000-10-11
HK1075417A1 (en) 2005-12-16
HUP0200781A2 (en) 2002-08-28
BR0009644A (pt) 2002-01-08
AU2004242454B2 (en) 2007-02-15
NO20014851L (no) 2001-12-07
ES2239953T3 (es) 2005-10-16
WO2000061174A3 (en) 2001-01-25
NO328983B1 (no) 2010-07-05
AU2004242454A1 (en) 2005-01-20
CA2303752A1 (en) 2000-10-08
PT1535623E (pt) 2009-03-19
DE60020442T2 (de) 2006-05-04
CN1367702A (zh) 2002-09-04
EP1043025B1 (en) 2005-06-01
PE20010026A1 (es) 2001-02-05
MXPA00003401A (es) 2002-03-08
EP1535623A1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
DE10084903T1 (de) Polyetherpolyurethan
DE60001530D1 (de) Verbinder
DE60006630D1 (de) Verbinder
DE60020922D1 (de) Verbinder
DE60042231D1 (de) Verbinder
DE69920862D1 (de) Verbinder
DE60008069D1 (de) Verbinder
DE60026459D1 (de) Simethicon enthaltendes Abführmittel
DE60019059D1 (de) Verbinder
DE60001032D1 (de) Verbinder
DE60037233D1 (de) Hämofiltrationsvorrichtung
DE60043606D1 (de) Verbinder
DE60025681D1 (de) Verbinder
DE60027520D1 (de) Verbinder
DE60015473D1 (de) Verbinder
HK1075417A1 (en) Renal cell carcinoma treatment
DE60026234D1 (de) Verbinder
DE60001783D1 (de) Verbinder
DE60003993D1 (de) Verbinder
DE60007475D1 (de) Filter
DE60014496D1 (de) Verbinder
DE60017062D1 (de) Verbinder
DE60012162D1 (de) Verbinder
DE60009806D1 (de) Verbinder
BR0009400B1 (pt) unidade filtrante do tipo célula.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees